Ythdf2 regulates cardiac remodeling through its mRNA target transcripts.

mA mRNA methylation controls cardiomyocyte function and increased overall mA levels are a stereotyping finding in heart failure independent of the underlying etiology. However, it is largely unknown how the information is read by mA reader proteins in heart failure. Here we show that the mA reader protein Ythdf2 controls cardiac function and identified a novel mechanism how reader proteins control gene expression and cardiac function.

The impact of tumor metabolic activity assessed by F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients.

Background: Selective uptake of (18)F-fluoro-ethyl-tyrosine (F-FET) is used in high-grade glioma (HGG) to assess tumor metabolic activity positron emission tomography (PET). We aim to investigate its value for target volume definition, as a prognosticator, and associations with whole-blood transcriptome liquid biopsy (WBT lbx) for which we recently reported feasibility to mirror tumor characteristics and response to particle irradiation in recurrent HGG (rHGG).

Methods: F-FET-PET data from n = 43 patients with primary glioblastoma (pGBM) and n = 33 patients with rHGG were assessed.

Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model.

Radiotherapy can act as an in situ vaccine, activating preventive tumor-specific immune responses in patients. Although carbon ion radiotherapy has superior biophysical properties over conventional photon irradiation, the immunological effects induced by this radiation type are poorly understood. Multiple strategies combining radiotherapy with immune checkpoint inhibition (radioimmunotherapy) to enhance antitumor immunity have been described; however, immune cell composition in tumors following radioimmunotherapy with carbon ions remains poorly explored.

AAMP is a binding partner of costimulatory human B7-H3.

Background: Targeted immunotherapies are of growing interest in the treatment of various cancers. B7 homolog 3 protein (B7-H3), a member of the co-stimulatory/-inhibitory B7-family, exerts immunosuppressive and pro-tumorigenic functions in various cancer types and is under evaluation in ongoing clinical trials. Unfortunately, interaction partner(s) remain unknown which restricts the druggability.